SCHEMBL1554832

SCHEMBL1554832

O=C(O)c1c(-c2cccc(Cl)c2Cl)csc1N1C(=O)c2ccccc2C1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 2/20 0.39
SCN2A Q99250 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
EIF4E P06730 1/20 0.37
TSHR P16473 1/20 0.36
HTR2C P28335 3/20 0.36
TLR7 Q9NYK1 1/20 0.36
AR P10275 2/20 0.35
PIM3 Q86V86 1/20 0.35
HIPK4 Q8NE63 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1554688 0.91 SCN2A (0.41) ANO1SCN2ACA12CA1CA2
SCHEMBL1553971 0.83 ALDH1A1 (0.46) MEN1KMT2ATSHRKDM4EALDH1A1
SCHEMBL1554791 0.81 ALDH1A1 (0.46) SCN2ACA12CA1CA2CA9
SCHEMBL1553923 0.81 AR (0.49) ANO1MEN1KMT2AARKDM4E
SCHEMBL1553944 0.80 POLB (0.44) SCN2ACA12CA1CA2CA9
SCHEMBL1554631 0.80 LMNA (0.42) ANO1MEN1KMT2AEIF4EAR
SCHEMBL1553830 0.80 TNF (0.44) ANO1MEN1KMT2AEIF4EAR
SCHEMBL1553666 0.77 ALDH1A1 (0.44) CA12CA1CA2CA9MEN1
SCHEMBL1554635 0.76 MEN1 (0.48) SCN2ACA12CA1CA2CA9
SCHEMBL1553831 0.75 MEN1 (0.46) ANO1SCN2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383463-B1 FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN KING PHARMACEUTICALS INC (US) 2011-04-27 EP disclosed
EP-1383463-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS INC (US) 2009-03-25 EP disclosed
US-7449490-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-11-11 US disclosed
US-7101905-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-09-05 US disclosed
US-20060183921-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-08-17 US disclosed
EP-1383463-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE King Pharmaceuticals, Inc. (US) 2004-01-28 EP disclosed
US-20030073733-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-04-17 US disclosed
WO-2002083083-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183921-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE ANO1 2797/4885SCN2A 354/4885CA12 2677/4885
US-20030073733-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE ANO1 2797/4885SCN2A 354/4885CA12 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.